Heterogeneity in DCE-MRI parametric maps: A biomarker for treatment response?

Lejla Alic, M. Van Vliet, C. F. Van Dijke, A. M M Eggermont, J. F. Veenland, W. J. Niessen

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

This study aims to quantify the heterogeneity of tumour enhancement in dynamic contrast-enhanced MRI (DCE-MRI) using texture analysis methods. The suitability of the coherence and the fractal dimension to monitor tumour response was evaluated in 18 patients with limb sarcomas imaged by DCE-MRI pre- and post-treatment. According to the histopathology, tumours were classified into responders and non-responders. Pharmacokinetic (Ktrans) and heuristic model-based parametric maps (slope, max enhancement, AUC) were computed from the DCE-MRI data. A substantial correlation was found between the pharmacokinetic and heuristic model-based parametric maps: ρ = 0.56 for the slope, ρ = 0.44 for maximum enhancement, and ρ = 0.61 for AUC. From all four parametric maps, the enhancing fraction, and the heterogeneity features (i.e. coherence and fractal dimension) were determined. In terms of monitoring tumour response, using both pre- and post-treatment DCE-MRI, the enhancing fraction and the coherence showed significant differences between the response group and the non-response group (i.e. the highest sensitivity (91%) for K trans, and the highest specificity (83%) for max enhancement). In terms of treatment prediction, using solely the pre-treatment DCE-MRI, the enhancing fraction and coherence discriminated between responders and non-responders. For prediction, the highest sensitivity (91%) was shared by Ktrans, slope and max enhancement, and the highest specificity (71%) was achieved by Ktrans. On average, tumours that responded showed a high enhancing fraction and high coherence on the pre-treatment scan. These results suggest that specific heterogeneity features, computed from both pharmacokinetic and heuristic model-based parametric maps, show potential as a biomarker for monitoring tumour response.

Original languageEnglish
Pages (from-to)1601-1616
Number of pages16
JournalPhysics in Medicine and Biology
Volume56
Issue number6
DOIs
Publication statusPublished - 21 Mar 2011
Externally publishedYes

Fingerprint

Biomarkers
Fractals
Pharmacokinetics
Neoplasms
Therapeutics
Area Under Curve
Tumor Biomarkers
Sarcoma
Extremities
Heuristics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Alic, L., Van Vliet, M., Van Dijke, C. F., Eggermont, A. M. M., Veenland, J. F., & Niessen, W. J. (2011). Heterogeneity in DCE-MRI parametric maps: A biomarker for treatment response? Physics in Medicine and Biology, 56(6), 1601-1616. https://doi.org/10.1088/0031-9155/56/6/006

Heterogeneity in DCE-MRI parametric maps : A biomarker for treatment response? / Alic, Lejla; Van Vliet, M.; Van Dijke, C. F.; Eggermont, A. M M; Veenland, J. F.; Niessen, W. J.

In: Physics in Medicine and Biology, Vol. 56, No. 6, 21.03.2011, p. 1601-1616.

Research output: Contribution to journalArticle

Alic, L, Van Vliet, M, Van Dijke, CF, Eggermont, AMM, Veenland, JF & Niessen, WJ 2011, 'Heterogeneity in DCE-MRI parametric maps: A biomarker for treatment response?', Physics in Medicine and Biology, vol. 56, no. 6, pp. 1601-1616. https://doi.org/10.1088/0031-9155/56/6/006
Alic, Lejla ; Van Vliet, M. ; Van Dijke, C. F. ; Eggermont, A. M M ; Veenland, J. F. ; Niessen, W. J. / Heterogeneity in DCE-MRI parametric maps : A biomarker for treatment response?. In: Physics in Medicine and Biology. 2011 ; Vol. 56, No. 6. pp. 1601-1616.
@article{a623abb60d914eef820fe59aaf78d385,
title = "Heterogeneity in DCE-MRI parametric maps: A biomarker for treatment response?",
abstract = "This study aims to quantify the heterogeneity of tumour enhancement in dynamic contrast-enhanced MRI (DCE-MRI) using texture analysis methods. The suitability of the coherence and the fractal dimension to monitor tumour response was evaluated in 18 patients with limb sarcomas imaged by DCE-MRI pre- and post-treatment. According to the histopathology, tumours were classified into responders and non-responders. Pharmacokinetic (Ktrans) and heuristic model-based parametric maps (slope, max enhancement, AUC) were computed from the DCE-MRI data. A substantial correlation was found between the pharmacokinetic and heuristic model-based parametric maps: ρ = 0.56 for the slope, ρ = 0.44 for maximum enhancement, and ρ = 0.61 for AUC. From all four parametric maps, the enhancing fraction, and the heterogeneity features (i.e. coherence and fractal dimension) were determined. In terms of monitoring tumour response, using both pre- and post-treatment DCE-MRI, the enhancing fraction and the coherence showed significant differences between the response group and the non-response group (i.e. the highest sensitivity (91{\%}) for K trans, and the highest specificity (83{\%}) for max enhancement). In terms of treatment prediction, using solely the pre-treatment DCE-MRI, the enhancing fraction and coherence discriminated between responders and non-responders. For prediction, the highest sensitivity (91{\%}) was shared by Ktrans, slope and max enhancement, and the highest specificity (71{\%}) was achieved by Ktrans. On average, tumours that responded showed a high enhancing fraction and high coherence on the pre-treatment scan. These results suggest that specific heterogeneity features, computed from both pharmacokinetic and heuristic model-based parametric maps, show potential as a biomarker for monitoring tumour response.",
author = "Lejla Alic and {Van Vliet}, M. and {Van Dijke}, {C. F.} and Eggermont, {A. M M} and Veenland, {J. F.} and Niessen, {W. J.}",
year = "2011",
month = "3",
day = "21",
doi = "10.1088/0031-9155/56/6/006",
language = "English",
volume = "56",
pages = "1601--1616",
journal = "Physics in Medicine and Biology",
issn = "0031-9155",
publisher = "IOP Publishing Ltd.",
number = "6",

}

TY - JOUR

T1 - Heterogeneity in DCE-MRI parametric maps

T2 - A biomarker for treatment response?

AU - Alic, Lejla

AU - Van Vliet, M.

AU - Van Dijke, C. F.

AU - Eggermont, A. M M

AU - Veenland, J. F.

AU - Niessen, W. J.

PY - 2011/3/21

Y1 - 2011/3/21

N2 - This study aims to quantify the heterogeneity of tumour enhancement in dynamic contrast-enhanced MRI (DCE-MRI) using texture analysis methods. The suitability of the coherence and the fractal dimension to monitor tumour response was evaluated in 18 patients with limb sarcomas imaged by DCE-MRI pre- and post-treatment. According to the histopathology, tumours were classified into responders and non-responders. Pharmacokinetic (Ktrans) and heuristic model-based parametric maps (slope, max enhancement, AUC) were computed from the DCE-MRI data. A substantial correlation was found between the pharmacokinetic and heuristic model-based parametric maps: ρ = 0.56 for the slope, ρ = 0.44 for maximum enhancement, and ρ = 0.61 for AUC. From all four parametric maps, the enhancing fraction, and the heterogeneity features (i.e. coherence and fractal dimension) were determined. In terms of monitoring tumour response, using both pre- and post-treatment DCE-MRI, the enhancing fraction and the coherence showed significant differences between the response group and the non-response group (i.e. the highest sensitivity (91%) for K trans, and the highest specificity (83%) for max enhancement). In terms of treatment prediction, using solely the pre-treatment DCE-MRI, the enhancing fraction and coherence discriminated between responders and non-responders. For prediction, the highest sensitivity (91%) was shared by Ktrans, slope and max enhancement, and the highest specificity (71%) was achieved by Ktrans. On average, tumours that responded showed a high enhancing fraction and high coherence on the pre-treatment scan. These results suggest that specific heterogeneity features, computed from both pharmacokinetic and heuristic model-based parametric maps, show potential as a biomarker for monitoring tumour response.

AB - This study aims to quantify the heterogeneity of tumour enhancement in dynamic contrast-enhanced MRI (DCE-MRI) using texture analysis methods. The suitability of the coherence and the fractal dimension to monitor tumour response was evaluated in 18 patients with limb sarcomas imaged by DCE-MRI pre- and post-treatment. According to the histopathology, tumours were classified into responders and non-responders. Pharmacokinetic (Ktrans) and heuristic model-based parametric maps (slope, max enhancement, AUC) were computed from the DCE-MRI data. A substantial correlation was found between the pharmacokinetic and heuristic model-based parametric maps: ρ = 0.56 for the slope, ρ = 0.44 for maximum enhancement, and ρ = 0.61 for AUC. From all four parametric maps, the enhancing fraction, and the heterogeneity features (i.e. coherence and fractal dimension) were determined. In terms of monitoring tumour response, using both pre- and post-treatment DCE-MRI, the enhancing fraction and the coherence showed significant differences between the response group and the non-response group (i.e. the highest sensitivity (91%) for K trans, and the highest specificity (83%) for max enhancement). In terms of treatment prediction, using solely the pre-treatment DCE-MRI, the enhancing fraction and coherence discriminated between responders and non-responders. For prediction, the highest sensitivity (91%) was shared by Ktrans, slope and max enhancement, and the highest specificity (71%) was achieved by Ktrans. On average, tumours that responded showed a high enhancing fraction and high coherence on the pre-treatment scan. These results suggest that specific heterogeneity features, computed from both pharmacokinetic and heuristic model-based parametric maps, show potential as a biomarker for monitoring tumour response.

UR - http://www.scopus.com/inward/record.url?scp=79952944800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952944800&partnerID=8YFLogxK

U2 - 10.1088/0031-9155/56/6/006

DO - 10.1088/0031-9155/56/6/006

M3 - Article

C2 - 21335648

AN - SCOPUS:79952944800

VL - 56

SP - 1601

EP - 1616

JO - Physics in Medicine and Biology

JF - Physics in Medicine and Biology

SN - 0031-9155

IS - 6

ER -